Roth Capital Positive on TG Therapeutics (TGTX) Following Publication of ASH Abstracts
Tweet Send to a Friend
Roth Capital reiterates its Buy/Focus Pick rating and $25 price target on TG Therapeutics (Nasdaq: TGTX) after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
